GoldBamboo.com - Knowledge is strong medicine
  

Comparison of Valsartan with Amlodipine in Hypertensive Patients with Glucose Intolerance - Article


  Not Signed In - Sign In / Register


Get Your Free Credit Report Right Now!

Zip Code:



General Topics A-Z

Valsartan and Hydrochlorothiazide

Diovan HCT 



Clinical Trial: Comparison of Valsartan with Amlodipine in Hypertensive Patients with Glucose Intolerance

This study is currently recruiting patients.
Verified by Nagoya University February 2005

Sponsored by: Nagoya University
Information provided by: Nagoya University
ClinicalTrials.gov Identifier: NCT00129233

Purpose

Various guidelines recommended angiotensin converting enzyme (ACE) inhibitor or angiotensin Ⅱ receptor-1 blocker (ARB) for hypertensive patients with diabetes on the basis of cardiac- and reno-protective effects of these drugs. However, these recommendations could not be extrapolated to Japanese, because Japan has been known as a country with low incidence of coronary artery disease and high incidence of cerebrovascular disease. Furthermore, calcium channel blocker (CCB) also was protective against renal function as well as ACE inhibitor in Japanese diabetic hypertensive patients. This study will test which of ARB or CCB is superior in treating Japanese diabetic hypertensive patients.
Condition Intervention Phase
Hypertension
Type 2 Diabetes Mellitus
Impaired Glucose Tolerance
  Drug: Valsartan (drug)
 Drug: Amlodipine (drug)
 Phase IV

MedlinePlus related topics:  Diabetes;   Genetic Disorders;   High Blood Pressure;   Metabolic Disorders

Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study

Official Title: The Novel Antihypertensive Goal Of hYpertension with diAbetes ― Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study

Further Study Details: 
Primary Outcomes: fatal or non-fatal myocardial infarction; fatal or non-fatal stroke; admission due to congestive heart failure; coronary revascularization; sudden cardiac death
Secondary Outcomes: total death; cardiac function evaluated by ultrasonography; incidence of atrial fibrillation/flutter; control of blood glucose; renal function

Study start: October 2004

Eligibility

Ages Eligible for Study:  30 Years   -   75 Years,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

Exclusion Criteria:

  • History of congestive heart failure, myocardial infarction, or coronary revascularization in the recent 6 months.
  • Taking calcium channel blocker for the purpose of angina pectoris
  • Reduced ejection fraction (<40%)
  • Second- or third-degree of atrioventricular block
  • Severe hypertension (>200/110 mmHg) or secondary hypertension
  • History of stroke in the recent 6 months
  • Serum creatinine >2.5 mg/dl
  • Estimated survival duration less than 3 years due to other conditions
  • Pregnant woman or possible pregnant woman

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00129233

Toyoaki Murohara, MD, PhD      81-52-744-2149    murohara@med.nagoya-u.ac.jp

Japan, Aichi
      Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya,  Aichi,  466-8550,  Japan; Recruiting
Toyoaki Murohara, MD, PhD  81-52-744-2149    murohara@med.nagoya-u.ac.jp 
Toyoaki Murohara, MD, PhD,  Principal Investigator

Study chairs or principal investigators

Toyoaki Murohara, MD, PhD,  Principal Investigator,  Department of Caldiology, Nagoya University Graduate School of Medicine   

More Information

Publications

Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004 Jun 19;363(9426):2022-31.

Study ID Numbers:  169
Last Updated:  August 10, 2005
Record first received:  August 10, 2005
ClinicalTrials.gov Identifier:  NCT00129233
Health Authority: Japan: Ministry of Health, Labor and Welfare
ClinicalTrials.gov processed this record on 2005-08-23


Source: ClinicalTrials.gov
Cache Date: August 24, 2005

Resources



[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $30 a year, a savings of 70% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Valsartan and Hydrochlorothiazide.

November 27, 2009


Page Updated: June 1, 2005
============== Advertisement ==============
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Health Forums

Copyright © 2004-2009 - Anaconda Partners LLC - All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.